Median Progression Free Survival (PFS) Up to 36 months [clinicaltrials_resource:c44b1fa523ccab26541b870f5fe94343]
Progression Free Survival is defined as the interval between the date of the first cetuximab administration and the date of objective progression of disease. Progression was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria. Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Median Progression Free Survival (PFS) Up to 36 months [clinicaltrials_resource:c44b1fa523ccab26541b870f5fe94343]
Progression Free Survival is defined as the interval between the date of the first cetuximab administration and the date of objective progression of disease. Progression was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria. Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
Bio2RDF identifier
c44b1fa523ccab26541b870f5fe94343
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:c44b1fa523ccab26541b870f5fe94343
measure [clinicaltrials_vocabulary:measure]
Median Progression Free Survival (PFS)
time frame [clinicaltrials_vocabulary:time-frame]
Up to 36 months
description
Progression Free Survival is d ...... f existing non-target lesions.
identifier
clinicaltrials_resource:c44b1fa523ccab26541b870f5fe94343
title
Median Progression Free Survival (PFS) Up to 36 months
@en
type
label
Median Progression Free Surviv ...... b1fa523ccab26541b870f5fe94343]
@en